Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome

British Journal of Cancer

Volumn 106, Issue 10, 2012, Pages 1682-1688

  Krakstad, C ^a,b   Trovik, J ^a,b   Wik, E ^a,b   Engelsen, I B ^b   Werner, H M J ^a,b   Birkeland, E ^a,b   Raeder, M B ^a,b   Yan, A M ^a,b   Stefansson, I M ^a   Kalland, K H ^a,b   Akslen, L A ^a   Salvesen, H B ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Endometrial cancer; ERa; GPER; HDAC inhibitor

Indexed keywords

BAS 012416453; CICLOPIROX; ECONAZOLE; ESTROGEN RECEPTOR ALPHA; G PROTEIN COUPLED ESTROGEN RECEPTOR; MESSENGER RNA; SULFACETAMIDE; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; WORTMANNIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; DISEASE COURSE; DRUG TARGETING; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; TREATMENT OUTCOME;

EID: 84860771546     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.91     Document Type: Article

References (34)

1. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2(7): 811-814 (Pubitemid 26225099)
2. Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, Black MA, Donato AL, Arterburn JB, Oprea TI, Prossnitz ER, Dun NJ, Jordan VC (2010) The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res 70(3): 1184-1194
3. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, Sklar LA, Oprea TI, Prossnitz ER (2006) Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2(4): 207-212
4. Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ (1997) Identification of a gene (GPR30) with homology to the G-proteincoupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 45(3): 607-617 (Pubitemid 27506136)
5. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z (2006) A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38(9): 1043-1048 (Pubitemid 44325930)
6. Chen S, Ye J, Kijima I, Evans D (2010) The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. Proc Natl Acad Sci USA 107(24): 11032-11037
7. Chen WY, Colditz GA (2007) Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer. Nat Clin Pract Oncol 4(7): 415-423 (Pubitemid 47039692)
8. Decruze SB, Green JA (2007) Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 17(5): 964-978 (Pubitemid 47414814)
9. Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK, Bologa CG, Leitao A, Brailoiu E, Deliu E, Dun NJ, Sklar LA, Hathaway HJ, Arterburn JB, Oprea TI, Prossnitz ER (2009) In vivo effects of a GPR30 antagonist. Nat Chem Biol 5(6): 421-427
10. Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologa CG, Oprea TI, Yamaguchi Y, Hayashi SI, Sklar LA, Hathaway HJ, Arterburn JB, Prossnitz ER (2011) Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J Steroid Biochem Mol Biol 127: 358-366
11. EBCTCG Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472): 1687-1717
12. Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB (2008) GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol 199(5): 543.e1-e7
13. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E (2006) Distribution of GPR30, a seven membranespanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 12(21): 6359-6366 (Pubitemid 44799705)
14. Filardo EJ, Quinn JA, Bland KI, Frackelton Jr AR (2000) Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14(10): 1649-1660
15. Filardo EJ, Quinn JA, Frackelton Jr AR, Bland KI (2002) Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 16(1): 70-84 (Pubitemid 34044499)
16. Gao F, Ma X, Ostmann AB, Das SK (2011) GPR30 activation opposes estrogen-dependent uterine growth via inhibition of stromal ERK1/2 and estrogen receptor alpha (ERalpha) phosphorylation signals. Endocrinology 152(4): 1434-1447
17. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313(5795): 1929-1935 (Pubitemid 44497995)
18. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta]CT method. Methods 25(4): 402-408 (Pubitemid 34164012)
19. Maggiolini M, Picard D (2010) The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol 204(2): 105-114
20. Poola I, Abraham J, Liu A, Marshalleck JJ, Dewitty RL (2008) The cell surface estrogen receptor, G protein-coupled receptor 30 (GPR30), is markedly down regulated during breast tumorigenesis. Breast Cancer 1: 65-78
21. Prossnitz ER, Barton M (2011) The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 7(12): 715-726
22. Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bo TH, Jonassen I, Thomas RK, Zander T, Garraway LA, Oyan AM, Sellers WR, Kalland KH, Meyerson M, Akslen LA, Beroukhim R (2009) Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 106(12): 4834-4839
23. Salvesen HB, Das S, Akslen LA (2000) Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 6(1): 153-159 (Pubitemid 30064988)
24. Salvesen HB, Iversen OE, Akslen LA (1999) Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 17(5): 1382-1390 (Pubitemid 29220843)
25. Singh M, Zaino RJ, Filiaci VJ, Leslie KK (2007) Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 106(2): 325-333 (Pubitemid 47087930)
26. Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER (2009) GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol 114(3): 465-471
27. Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE, Prossnitz ER (2007) GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol 196(4): 386.e1-9; discussion 386.e9-e11
28. Stefansson IM, Salvesen HB, Akslen LA (2004) Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 22(7): 1242-1252 (Pubitemid 41079838)
29. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I, Koeffler HP (2004) Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10(3): 1141-1149 (Pubitemid 38198916)
30. Takai N, Narahara H (2010) Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer. Obstet Gynecol Int 2010: 923824
31. Thomas C, Gustafsson JA (2011) The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 11(8): 597-608
32. Thomas P, Pang Y, Filardo EJ, Dong J (2005) Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146(2): 624-632 (Pubitemid 40129818)
33. Thomas S, Munster PN (2009) Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett 280(2): 184-191
34. Trovik J, Wik E, Stefansson IM, Marcickiewicz J, Tingulstad S, Staff AC, Njolstad TS, Vandenput I, Amant F, Akslen LA, Salvesen H (2011) Stathmin overexpression identifies high risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res 17(10): 3368-3377